FDA Approved Indications for this Orphan Drug:

Treatment of moderate to severe hidradenitis suppurativa

FDA Marketing Approval issued as of:
09/09/2015

Orphan Drug exclusivity ends on:
09/09/2022
Company Making and Marketing this drug:
AbbVie, Inc.

FDA Designation Date:
5/13/15

FDA Drug Designation:
Treatment of moderate to severe hidradenitis suppurativa (Hurley stage 2 and Hurley stage 3 disease)